The MaxQ AI Intracranial Hemorrhage (ICH) platform will now be available through the EnvoyAI Exchange marketplace following a new distribution agreement between the two companies.
MaxQ AI, an Israel-based clinical diagnostics intelligence platform, announced its agreement with EnvoyAI, a subsidiary of TeraRecon, earlier this week. The agreement means MaxQ AI’s Accipio ICH platform will be a clinical solution available through the EnvoyAI Exchange marketplace, according to a press release. The platform will also work in combination with TeraRecon’s Northstar AI Results Explorer.
Additionally, the company’s Accipio Ix ICH platform will be sold through EnvoyAI and TeraRecon’s picture archiving and communication system (PACS) distribution channels. In early November, the Accipio Ix ICH platform received 510(k) clearance from the FDA, meaning it can be sold commercially in the United States. The platform is designed to detect the presence of brain bleeds and help prioritize patients for physicians.
"Our agreement with EnvoyAI will enable hospitals around the world to have access to our revolutionary AI-enabled Accipio platform for approved commercial use in their emergency rooms and for clinical research purposes," Chris Schnee, senior vice president of commercial operations for MaxQ AI, said in a prepared statement. "This partnership further accelerates the adoption of MaxQ solutions by acute care hospitals, which are TeraRecon's core customer base. We are proud to be collaborating commercially with a market share leader in radiology advanced visualization.”
Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls.